Verastem, Inc. (NASDAQ: VSTM) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt.
November 9, 2015
Verastem Reports Third Quarter 2015 Financial and Corporate Results
November 4, 2015
Verastem to Present Preclinical Data at SITC 2015
October 27, 2015
Verastem to Present Preclinical Data at the 2015 EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
The majority of cancer drugs, while killing the bulk of tumor cells, ultimately fail to induce durable clinical responses. A reason for this failure may be the presence of a minority of cells in the tumor called cancer stem cells which are resistant to existing cancer therapies.
Using our proprietary technology we are identifying and developing drugs that target and kill cancer stem cells.